Pipeline

VRN02, DYRK1A, Autoimmune Disease

VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.

Pipeline

VRN04, RIPK1, Autoimmune diseases

VRN04 program is under development for the treatment of inflammatory diseases, by inhibiting RIPK1 kinase activity. Series of animal experiments have suggested that VRN04 has efficacy for major inflammatory diseases such as acute lung injury, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, and we are expanding into other indications.

Pipeline

VRN08, TTK, Triple-negative Breast cancer

Voronoi’s VRN08 program aims to treat TNBC by targeting TTK. We plan to expand indication to other solid tumors like pancreatic cancer and brain cancer. As TNBC, pancreatic cancer, and brain cancer are areas where existing targeted therapeutics and immuno-oncology drugs have little efficacy, development of effective and safe therapeutics is urgently needed.

Pipeline

VRN02, DYRK1A, Autoimmune diseases

VRN02 program is under development for the treatment of autoimmune diseases, by inhibiting DYRK1A kinase activity. Series of animal experiments have suggested that VRN02 has efficacy for major autoimmune diseases such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and atopic dermatitis, and we are expanding into other indications. VRN02 is under development not only as oral pills, but also as topical formulation to apply on skin.

Pipeline

VRN01, LRRK2, Glioblastoma

VRN01 program is under development for the treatment of brain tumor, especially GBM (Glioblastoma multiforme) which is known to be the most malignant form of brain tumor, by inhibiting LRRK2 kinase activity.

Meet the experts

Creating innovation with Harvard

Dr. Bae is in charge of Voronoi’s joint international research, including joint research in Boston with Dr. Nathanael Gray, a professor at Dana-Farber Cancer Institute and Harvard Medical School.

Pipeline

Brain Tumor

We are developing a new therapy targeting brain tumor stem cells, a cause of brain tumor relapse. We are working to treat GBM, or Glioblastoma, the most malignant form of brain cancer.

Pipeline

Alzheimer’s Disease

We are developing a therapy that targets both amyloid beta and tau.
Animal tests have proven that Voronoi’s candidate significantly suppresses them and
substantially improves cognitive function.

Pipeline

Chronic Inflammatory Disease

TNF- α is well known as a core cause of inflammation, accompanied by autoimmune diseases. Voronoi has identified a candidate compound that blocks signal transduction of TNF- α. We are now developing therapies for rheumatoid arthritis, inflammatory bowel disease, systemic psoriasis, xerophthalmia, macular degeneration and degenerative brain disease.

Pipeline

Non-Small-Cell Lung Carcinoma

We identified a candidate that can overcome the EGFR (Epidermal growth factor receptor) resistance issues existing cancer drugs had. The candidate is being developed as therapy for lung cancer and various solid cancers.

Pipeline

Pipeline

We focus on developing therapies for intractable and rare diseases.

Meet the experts

Nathanael Gray, PhD

​Nathanael Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute.

Our work

About Voronoi

Voronoi develops novel TPD (Target protein degraders) and kinase inhibitors with the aim to treat intractable and rare diseases. We are developing competitive therapies based on deep understanding of diseases and innovative technologies.

Company structure

Voronoi Group Structure

Voronoi Group consists of the parent company Voronoi and its subsidiaries Voronoi Bio and B2S Bio. Voronoi leads clinical development throughout the R&D journey. Voronoi Bio focuses on R&D of molecular modeling and kinase inhibitor, and B2S Bio focuses on TPD.

People

Meet the experts

Our experts and the management bring to the team years of experience and expertise in various fields.

2019-11-20T09:01:38+00:00
KoreaUSA